US Stocks Mixed Ahead Of Fed Decision; Dow Surges 100 Points

U.S. stocks traded mixed as the Dow rose about 0.23% (~100 points) to 47,669.92 while the Nasdaq fell 0.19% and the S&P 500 was essentially flat; industrials led gains (+0.8%) and information technology lagged (-0.6%). Chewy topped estimates for Q3 with adjusted EPS of $0.32 (consensus $0.13) and revenue of $3.117 billion, marginally above expectations and within management guidance, underscoring resilience in pet retail. Several small caps and SPACs saw extreme volatility—A SPAC III Acquisition jumped 336%, Beasley Broadcast +135% and Enveric Biosciences +102% after a U.S. patent notice—while a handful of microcaps plunged; commodities and global bourses were mixed (oil down to $57.92, gold modestly lower). On the data front, U.S. compensation costs eased to +0.8% in Q3 (from 0.9%) and mortgage applications rose 4.8% in the first week of December, a combination that may modestly temper near-term inflation concerns while signalling renewed housing activity.

Analysis

U.S. equities were mixed on Wednesday: the Dow rose about 0.23% (~100 points) to 47,669.92, the NASDAQ declined 0.19% to 23,530.68, and the S&P 500 was essentially flat at 6,842.14. Industrials led gains (+0.8%) while information technology lagged (-0.6%), and global bourses showed a patchwork of small moves (STOXX 600 +0.1%, FTSE +0.3%, DAX -0.3%, Nikkei -0.10%).

Chewy reported third-quarter adjusted EPS of $0.32 versus a $0.13 consensus and revenue of $3.117 billion, up 8.3% year-over-year and slightly above consensus and within management guidance; this signals resilience in pet retail demand and could support consumer-discretionary sentiment near term. Several microcaps and SPACs saw extreme idiosyncratic volatility—A SPAC III Acquisition jumped 336% to $45.69, Beasley Broadcast +135% to $9.52—while WORK, Agape ATP and Pomdoctor plunged 86%, 82% and 73% respectively, underscoring pronounced retail-driven swings.

Enveric Biosciences rallied 102% to $11.94 after a U.S. Patent Office Notice of Allowance for its EVM301 series, a near-term catalyst for the biotech but one that remains speculative absent clinical outcomes. On macro data, civilian compensation costs eased to +0.8% in Q3 (from 0.9%) and mortgage applications rose 4.8% in early December; the mix marginally tempers near-term inflation concerns while pointing to renewed housing activity, which should be monitored for Fed and rate-sensitivity implications.

Key Decisions for Investors

• Consider adding or modestly overweight CHWY on the earnings beat and 8.3% revenue growth, but monitor customer-repeat rates and margin trends in upcoming reports
• Avoid chasing extreme moves in microcaps and SPACs like ASPC and BBGI; if participating, use very tight position sizing and stop-losses given the demonstrated volatility
• Treat ENVB’s patent allowance as a short-term positive catalyst suitable for a small, speculative allocation, but require clinical progress or partnership news before increasing exposure
• Increase vigilance on inflation and housing leads given compensation growth slowing to 0.8% and mortgage applications up 4.8%; consider favoring larger-cap, rate-resilient names over cyclical small caps until the macro picture clarifies
• Trim highly leveraged or illiquid small-cap positions after large one-day rallies, and rotate marginal risk exposure toward sectors leading the session (industrials) while waiting for a clearer IT recovery signal